Clinical and Pharmacologic Evaluation of Cefazolin in Children

Publisher Website
Google Scholar
Abstract
Children between six months and 15 years of age with pneumonia, osteomyelitis, gastroenteritis, or infections of soft tissue were treated with cefazolin parenterally. Prior to initiation of therapy, blood and other appropriate material from the site of infection were obtained for smear and bacterial culture. The first 12 patients received cefazolin im in a dose of 25–50 mg/kg per day. An additional 19 patients participated in a randomized protocol, in which the majority of patients received either cefazolin (50 mg/kg per day) or cephalothin (100 mg/kg per day). When organisms susceptible to cefazolin had been isolated, the clinical response to cefazolin was satisfactory in every case. Significant adverse effects of therapy were not encountered. Concentrations of drug in serum after im administration of 6.25 mg/kg doses of cefazolin exceeded the serum concentrations after im administration of 25 mg/kg of cephalothin. Following iv therapy, higher concentrations of cefazolin were obtained than after im administration.

This publication has 0 references indexed in Scilit: